Alexion is a global biopharmaceutical company focused on serving patients and families affected by rare diseases through the discovery, development and commercialization of life-changing medicines.

Alexion has made its name by developing Soliris (eculizumab), first launched in 2007, and is on track to earn $2.5 billion this year through treating two life-threatening and ultra-rare disorders ...

Alexion has said it can ramp up production if the drug works in trials but what it has not mentioned is its cost: Ultomiris is hugely expensive when used in rare diseases, costing several thousand ...

Alexion studies rare diseases, including two in the rare neurology space: generalized myasthenia gravis (gMG), which causes muscle weakness, and neuromyelitis optica spectrum disorder (NMOSD ...

Bkemv is being offered at 10% off Soliris, and Epysqli is offered at 30% below Soliris. Both biosimilars treat several of the ...

The company has decided to switch gears following disappointing data for a monoclonal antibody targeting a rare maternal ...

Based on the terms of the agreement, BridgeBio will receive a $30 million milestone payment upon approval in Japan, as well ...

Alexion, AstraZeneca Rare Disease has received the US Food and Drug Administration's (FDA) approval for Voydeya (danicopan) as an add-on therapy to treat extravascular haemolysis (EVH) in adults ...

BridgeBio Pharma’s Beyonttra to treat transthyretin-mediated amyloid cardiomyopathy receives Japanese approval: Palo Alto, California Monday, March 31, 2025, 17:00 Hrs [IST] Bri ...

Alexion, AstraZeneca Rare Disease, and DHL Express have teamed up to initiate Ireland's “first” complete transition to sustainable aviation fuel (SAF) for the international air delivery of ...

In the Japanese Phase 3 study, 0% mortality was reported over the 30-month treatment period and acoramidis was well-toleratedThe approval was ...